MeiraGTx Holdings PLC expected to post a loss of 46 cents a share - Earnings Preview
MeiraGTx Holdings PLC expected to post a loss of 46 cents a share - Earnings Preview
MeiraGTx Holdings PLC MGTX.OQ MGTX.O is expected to show a rise in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2026
The New York City-based company is expected to report a 238.0% increase in revenue to $12.476 million from $3.69 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for MeiraGTx Holdings PLC is for a loss of 46 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for MeiraGTx Holdings PLC is $26.00, about 98.9% above its last closing price of $13.07
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.43 | -0.40 | -0.57 | Missed | -42 |
Dec. 31 2026 | -0.57 | 0.19 | Beat | 133 | |
Sep. 30 2025 | -0.51 | -0.49 | -0.62 | Missed | -26.5 |
Jun. 30 2025 | -0.47 | -0.47 | -0.48 | Missed | -2.7 |
Mar. 31 2025 | -0.48 | -0.49 | -0.51 | Missed | -4.8 |
Dec. 31 2024 | -0.64 | -0.56 | -0.50 | Beat | 10.7 |
Sep. 30 2024 | -0.51 | -0.52 | -0.55 | Missed | -4.8 |
Jun. 30 2024 | -0.38 | -0.40 | -0.76 | Missed | -90 |
This summary was machine generated August 10 at 13:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on MeiraGTx Holdings
See all newsU.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
MeiraGTx gains; reports over $200 mln in license revenue
MeiraGTx Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
MeiraGTx Q2 revenue jumps on Reogen license revenue
Brief: Graviton Bioscience Announces Clearance Of Investigational New Drug For GV101 For Treatment Of Friedreich's Ataxia